EcoDrugPlus

Mineralocorticoid Receptor-Like

Ensembl ID : ENSECRG00000005960
Gene Symbol: LOC114652347
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSECRG00000019848
Gene Symbol: MAPK1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSECRG00000022844
Gene Symbol: LOC114661713
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSECRG00000013179
Gene Symbol: MAPK10
3 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSECRG00000001832
Gene Symbol: MAPK11
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSECRG00000012813
Gene Symbol: MAPK14
3 Cross references
295 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSECRG00000022512
Gene Symbol: MAPK8
3 Cross references
295 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSECRG00000018513
Gene Symbol: MAPK9
3 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSECRG00000017617
Gene Symbol: MAP2K1
3 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSECRG00000018359
Gene Symbol: MAP2K2
3 Cross references
273 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSECRG00000008003
Gene Symbol: MAP3K1
3 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSECRG00000000065
Gene Symbol: MAP3K10
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).